| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sandra George, Silvia Paulick, Ilka Knütter, Nadja Röber, Rico Hiemann, Dirk Roggenbuck, Karsten Conrad, Jan-Heiner Küppe. Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of myasthenia gravis. PloS one. vol 9. issue 1. 2014-09-08. PMID:24416182. |
while up to 95% of patients with generalized myasthenia gravis were shown to be positive for acetylcholine receptor-specific autoantibodies, up to 70% of the remaining patients develop autoantibodies against musk. |
2014-09-08 |
2023-08-12 |
human |
| Mayank Chauhan, Tanel Punga, Anna Rostedt Pung. Muscle-specific regulation of the mTOR signaling pathway in MuSK antibody seropositive (MuSK+) experimental autoimmune Myasthenia gravis (EAMG). Neuroscience research. vol 77. issue 1-2. 2014-06-19. PMID:23933211. |
muscle-specific regulation of the mtor signaling pathway in musk antibody seropositive (musk+) experimental autoimmune myasthenia gravis (eamg). |
2014-06-19 |
2023-08-12 |
mouse |
| Inga Koneczny, Judith Cossins, Angela Vincen. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. Journal of anatomy. vol 224. issue 1. 2014-06-13. PMID:23458718. |
the role of muscle-specific tyrosine kinase (musk) and mystery of musk myasthenia gravis. |
2014-06-13 |
2023-08-12 |
Not clear |
| Inga Koneczny, Judith Cossins, Angela Vincen. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. Journal of anatomy. vol 224. issue 1. 2014-06-13. PMID:23458718. |
musk myasthenia gravis is a rare, severe autoimmune disease of the neuromuscular junction, only identified in 2001, with unclear pathogenic mechanisms. |
2014-06-13 |
2023-08-12 |
Not clear |
| Canan Ulusoy, Eunmi Kim, Erdem Tüzün, Ruksana Huda, Vuslat Yılmaz, Konstantinos Poulas, Nikos Trakas, Lamprini Skriapa, Athanasios Niarchos, Richard T Strait, Fred D Finkelman, Selin Turan, Paraskevi Zisimopoulou, Socrates Tzartos, Güher Saruhan-Direskeneli, Premkumar Christados. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clinical immunology (Orlando, Fla.). vol 151. issue 2. 2014-05-16. PMID:24589747. |
myasthenia gravis (mg) is an autoimmune disease characterized by muscle weakness associated with acetylcholine receptor (achr), muscle-specific receptor kinase (musk) or low-density lipoprotein receptor-related protein 4 (lrp4)-antibodies. |
2014-05-16 |
2023-08-12 |
mouse |
| Canan Ulusoy, Eunmi Kim, Erdem Tüzün, Ruksana Huda, Vuslat Yılmaz, Konstantinos Poulas, Nikos Trakas, Lamprini Skriapa, Athanasios Niarchos, Richard T Strait, Fred D Finkelman, Selin Turan, Paraskevi Zisimopoulou, Socrates Tzartos, Güher Saruhan-Direskeneli, Premkumar Christados. Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clinical immunology (Orlando, Fla.). vol 151. issue 2. 2014-05-16. PMID:24589747. |
the musk associated experimental autoimmune myasthenia gravis (eamg) model was established in mice to investigate immunoglobulin (ig) and cytokine responses related with musk immunity. |
2014-05-16 |
2023-08-12 |
mouse |
| Ha Young Shin, Hyung Jun Park, Hyo Eun Lee, Young-Chul Choi, Seung Min Ki. Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity. Journal of clinical neurology (Seoul, Korea). vol 10. issue 2. 2014-05-15. PMID:24829597. |
patients with muscle-specific tyrosine kinase (musk) antibody (musk-ab)-positive myasthenia gravis (mg) show distinct responses to acetylcholinesterase inhibitors (acheis). |
2014-05-15 |
2023-08-13 |
Not clear |
| Masakatsu Motomura, Osamu Higuch. [Progress of myasthenia gravis: discovery of Lrp4 antibodies]. Rinsho shinkeigaku = Clinical neurology. vol 52. issue 11. 2014-04-21. PMID:23196599. |
myasthenia gravis (mg) is caused by the failure of neuromuscular transmission mediated by pathogenic autoantibodies (abs) against acetylcholine receptor (achr) and muscle-specific receptor tyrosine kinase (musk). |
2014-04-21 |
2023-08-12 |
Not clear |
| Kinji Ohn. [Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK]. Rinsho shinkeigaku = Clinical neurology. vol 52. issue 11. 2014-04-21. PMID:23196600. |
[anti-musk antibodies in myasthenia gravis block binding of collagen q to musk]. |
2014-04-21 |
2023-08-12 |
mouse |
| Kinji Ohn. [Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK]. Rinsho shinkeigaku = Clinical neurology. vol 52. issue 11. 2014-04-21. PMID:23196600. |
in myasthenia gravis (mg), 5-15% of patients are positive for musk antibodies. |
2014-04-21 |
2023-08-12 |
mouse |
| R Nakata, M Motomura, T Masuda, H Shiraishi, M Tokuda, T Fukuda, T Ando, T Yoshimura, M Tsujihata, A Kawakam. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. European journal of neurology. vol 20. issue 9. 2014-04-09. PMID:23679930. |
the differences in the characteristics of thymus histology, coexisting autoimmune diseases and related autoantibodies between anti-muscle-specific receptor tyrosine kinase (musk)-antibody (ab)-positive myasthenia gravis (mg) patients, and anti-acetylcholine receptor (achr)-ab-positive mg patients are not clearly defined. |
2014-04-09 |
2023-08-12 |
Not clear |
| J P Sie. Myasthenia gravis: an update for the clinician. Clinical and experimental immunology. vol 175. issue 3. 2014-04-08. PMID:24117026. |
myasthenia gravis should be classified according to the antibody specificity [acetylcholine, muscle-specific receptor tyrosine kinase (musk), low-density lipoprotein receptor-related protein 4 (lrp4), seronegative], thymus histology (thymitis, thymoma, atrophy), age at onset (in children; aged less than or more than 50 years) and type of course (ocular or generalized). |
2014-04-08 |
2023-08-12 |
Not clear |
| David Lacomis, Ahmed El-Dokl. What's in the literature? Journal of clinical neuromuscular disease. vol 15. issue 1. 2014-03-20. PMID:23965408. |
a new study of thymus histopathology in muscle-specific tyrosine kinase (musk) myasthenia gravis is covered and another article on the use of thymectomy. |
2014-03-20 |
2023-08-12 |
Not clear |
| Yu Chen, Hua-bing Wang, Yong-jun Wan. [Experimental autoimmune model of muscle-specific kinase specific myasthenia gravis in rats]. Zhonghua yi xue za zhi. vol 93. issue 17. 2014-03-10. PMID:24029475. |
to establish the experimental autoimmune lewis rat model of myasthenia gravis (eamg) specific for muscle-specific kinase (musk). |
2014-03-10 |
2023-08-12 |
rat |
| Maartje G Huijbers, Wei Zhang, Rinse Klooster, Erik H Niks, Matthew B Friese, Kirsten R Straasheijm, Peter E Thijssen, Hans Vrolijk, Jaap J Plomp, Pauline Vogels, Mario Losen, Silvère M Van der Maarel, Steven J Burden, Jan J Verschuure. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proceedings of the National Academy of Sciences of the United States of America. vol 110. issue 51. 2014-02-24. PMID:24297891. |
musk igg4 autoantibodies cause myasthenia gravis by inhibiting binding between musk and lrp4. |
2014-02-24 |
2023-08-12 |
mouse |
| Vasiliki Zouvelou, Eleftherios Stamboulis, Lambrini Skriapa, Socrates J Tzarto. MuSK-Ab positive myasthenia: not always grave. Journal of the neurological sciences. vol 331. issue 1-2. 2014-02-07. PMID:23706725. |
antibodies (abs) to muscle-specific tyrosine kinase (musk) are detected in approximately 40% of generalized acetylcholine receptor antibody-negative myasthenia gravis (mg). |
2014-02-07 |
2023-08-12 |
Not clear |
| Khalid El-Salem, Ahmed Yassin, Kefah Al-Hayk, Salma Yahya, Duha Al-Shorafat, Said S Dahbou. Treatment of MuSK-Associated Myasthenia Gravis. Current treatment options in neurology. vol 16. issue 4. 2014-02-07. PMID:24504626. |
approximately 5-8 % of myasthenia gravis (mg) patients test positive for antibodies against muscle- specific tyrosine kinase (musk) receptors. |
2014-02-07 |
2023-08-12 |
Not clear |
| Khalid El-Salem, Ahmed Yassin, Kefah Al-Hayk, Salma Yahya, Duha Al-Shorafat, Said S Dahbou. Treatment of MuSK-Associated Myasthenia Gravis. Current treatment options in neurology. vol 16. issue 4. 2014-02-07. PMID:24504626. |
while musk myasthenia gravis (mmg) patients have distinct clinical phenotypes and may differ from achr-positive patients in diagnostic testing and response to treatment, goals for the treatment of mmg are similar to those in non-mmg. |
2014-02-07 |
2023-08-12 |
Not clear |
| John S Yi, Emily C Decroos, Donald B Sanders, Kent J Weinhold, Jeffrey T Guptil. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle & nerve. vol 48. issue 6. 2014-01-13. PMID:24006142. |
prolonged b-cell depletion in musk myasthenia gravis following rituximab treatment. |
2014-01-13 |
2023-08-12 |
Not clear |
| Benison Keung, Kimberly R Robeson, Daniel B DiCapua, Jennifer B Rosen, Kevin C O'Connor, Jonathan M Goldstein, Richard J Nowa. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. Journal of neurology, neurosurgery, and psychiatry. vol 84. issue 12. 2014-01-09. PMID:23761915. |
long-term benefit of rituximab in musk autoantibody myasthenia gravis patients. |
2014-01-09 |
2023-08-12 |
Not clear |